What the trial was testing
The BRUIN enrolled 166 patients with mantle cell lymphoma. The study was sponsored by Loxo Oncology and tracked outcomes across the full group of patients who matched the trial's eligibility profile.
It was an early-stage trial — researchers are still confirming safety and getting an early look at how well the treatment works. Trials at this stage are designed to produce evidence regulators and physicians can act on — not just observations to follow up later.
What the results showed
58% of patients responded after their previous BTK inhibitor stopped working.
Journal of Clinical Oncology · 2023 · NCT03740529
These findings — that saw their mantle cell lymphoma respond to pirtobrutinib after other BTK inhibitors stopped working — were published in the Journal of Clinical Oncology and represent the headline result of the study.
Researchers tracked outcomes across 166 patients enrolled in the trial. The result was consistent enough across the group that the team felt confident reporting it.
What this means for patients
For patients with mantle cell lymphoma, this result changes the calculus on what to ask their care team about. Whether it changes day-to-day care depends on factors like disease subtype, prior treatments, and where the patient is in their care journey.
What you can do now
Pirtobrutinib (Jaypirca) received FDA accelerated approval in January 2023 for relapsed or refractory mantle cell lymphoma after at least two prior therapies, including a BTK inhibitor. It's a daily pill taken at home — a meaningful option when standard BTK drugs stop working, and when CAR-T therapy isn't right for you. Ask your oncologist whether you qualify.
Eligibility for the treatments mentioned above depends on specific test results and clinical history. Bring this summary, the trial name, and your most recent labs or pathology report to your next visit.
Open mantle cell lymphoma trials
Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader
This study aims to explore the recommended phase 2 dose and evaluate the safety, tolerability and preliminary antitumor activity of BGB-16673 monotherapy at the recommended Phase 2 dose for the selected B-cell malignancy expansion cohorts
Auto Stem Cell Transplant for Lymphoma Patients
This is a phase II study of autologous transplant for patients with Hodgkin (HL) and non-Hodgkin lymphomas (NHL) including those who are HIV positive.